Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 13, 2024 02:00 ET | Source: Sandoz Group

Sandoz reports fourth quarter 2023 sales and full-year 2023 results

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong fourth quarter performance, with net sales1 of USD 2.5 billion, up 10% in constant currencies (up...
March 05, 2024 13:24 ET | Source: Sandoz Group

Sandoz receives FDA approval for first and only denosumab biosimilars

MEDIA RELEASE Wyost® (denosumab-bddz) and Jubbonti® (denosumab-bddz) interchangeable with and approved by FDA for all indications of reference medicines Xgeva ®* (denosumab) and Prolia®*...
March 05, 2024 01:00 ET | Source: Sandoz Group

Sandoz announces nominations to the Board of Directors and leadership change

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Mathai Mammen and Michael Rechsteiner nominated to stand for election to Sandoz Board of Directors at upcoming...
March 04, 2024 01:00 ET | Source: Sandoz Group

Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market

MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab injection) for all approved indicationsDedicated retina sales and field reimbursement team...
February 29, 2024 01:00 ET | Source: Sandoz Group

Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Sandoz US to pay USD 265 million in exchange for full release of all claims by the classResolves...
February 01, 2024 01:15 ET | Source: Sandoz Group

Sandoz announces changes in the Board of Directors

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Graeme Pitkethly nominated as candidate for election to the Sandoz Board of Directors at the upcoming Annual...
January 31, 2024 01:00 ET | Source: Sandoz Group

Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Tyruko® approved for all indications of reference medicine Tyruko® biosimilar to treat...
January 22, 2024 01:00 ET | Source: Sandoz Group

Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®**...
November 21, 2023 01:00 ET | Source: Sandoz Group

Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve patient care

Biosimilar Hyrimoz® (adalimumab) citrate-free high-concentration formulation (HCF) indicated for all conditions of reference medicine Humira®* Hyrimoz® HCF to launch progressively across...
November 10, 2023 08:02 ET | Source: Sandoz Group

Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center in Germany

Investment of EUR 175 million reaffirms Sandoz commitment to long-term leadership in off-patent medicinesNew penicillin production process will significantly improve ecological footprint and help...